Featured Story | By Nick Paul Taylor Mirati Therapeutics is looking to a KRAS-Keytruda combination to give it an edge over Amgen in lung cancer. After lowering the dose of its KRAS drug, Mirati saw around 60% of first-line patients respond to the combination—and lessened the tolerability concerns that initially held back the cocktail. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Novartis has hacked off another piece of its $2.6 billion deal with Xencor, terminating its rights to a CD123xCD3 blood cancer bispecific that had a troubled time in early clinical development. read more By Kyle LaHucik Just three months after a $1.2 billion pact with Vertex, Arbor Biotechnologies has hauled in $215 million in a series B to bankroll its work in gene editing tech. The round includes financing from Vertex, Temasek, Ally Bridge Group and TCG Crossover. read more Sponsored by: IPM.ai Rare diseases demand a modern recruitment approach grounded in uncovering the ideal, medically-eligible patient population with the highest propensity for study enrollment and retention. read more By Kyle LaHucik In its quest to revive a failed Taisho depression drug, Ancora Bio needed a leader with experience getting a therapy to market for the depression field. So, the Joe Jimenez-founded biotech has snagged Sage CMO Stephen Kanes, who secured the first FDA approval for a postpartum depression drug. read more By Kyle LaHucik After rebranding from SciFluor Life Sciences and adding Centrexion co-founder Kerrie Brady as CEO last year, OcuTerra Therapeutics is ready for its next phase. The biotech secured $35 million to bankroll a phase 2 trial of its single asset. read more By Kyle LaHucik Flagship helped lead the way in messenger RNA by incubating Moderna. Now, the biotech founder wants to revolutionize transfer RNAs with $50 million dedicated to Flagship's newest venture, Alltrna. read more By Andrea Park Three years after Alcon pulled its CyPass Micro-Stent from the market due to safety concerns, the Novartis spinoff has found another glaucoma treatment device to take its place. read more By Robert King Drugmakers got mixed results in two legal rulings on their ability to restrict sales of drugs discounted under the 340B program to contract pharmacies. read more By Angus Liu Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing. Opdivo added to neoadjuvant chemotherapy before surgery improved event-free survival in early lung cancer, the company said. read more Resources Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Blue Matter Consulting Paper describing how the chronic insomnia market offers big lessons for any biopharma company thinking about getting into digital therapeutics in any therapeutic area. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: TransPerfect Life Sciences Every detail is important when selecting a new eCOA solution; learn more about the current eCOA landscape, best practices, and crucial considerations for successful eCOA solution deployment in this white paper. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
